Sanofi has received approval from the European Commission to expand the use of its MenQuadfi vaccine to include infants as young as six weeks old. This means the vaccine can now be given to protect babies against invasive meningococcal disease, which is caused by certain types of bacteria called serogroups A, C, W, and Y. Previously, MenQuadfi was only approved for children aged 12 months and older. The vaccine helps prevent a serious infection that can become life-threatening very quickly, sometimes within 24 hours of the first symptoms. Infants are especially at risk, with higher chances of death or long-term complications such as losing limbs, hearing loss, or brain damage. While serogroup A infections are now rare in Europe, serogroups C, W, and Y still cause a significant number of cases, making broad protection important from early infancy. Dr. Federico Martinon‑Torres, a pediatrician and researcher from Spain, emphasized that meningococcal disease progresses rapidly and is most dangerous for young children. Having a vaccine that can be given early in infancy allows doctors to include it in routine vaccination schedules, making it easier to protect more babies. The approval is based on strong scientific evidence showing that MenQuadfi works well in infants. Bogdana Coudsy from Sanofi explained that this decision reflects their commitment to protecting the youngest and most vulnerable children in Europe, giving doctors an additional tool to prevent this serious disease from the very beginning of life. This approval also highlights Sanofi’s ongoing efforts to make vaccines more accessible to those who need them most across the European Union.